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Background: Acute lung injury (ALI) is a serious clinical concern brought on by inflammatory triggers and is
characterized by rapid onset of respiratory distress in the setting of inflammatory insult. Fibrin deposition
from the inflammation leads to poor ventilation and perfusion. There is no current treatment for ALI other
than supportive measures. Heparin is an anticoagulant that prevents fibrin deposition. Previous animal and
ALI model studies have demonstrated improvement in lung function markers with nebulized heparin. This
review looks at the effects of nebulized heparin in treating ALI in mechanically ventilated patients.
Methods: An exhaustive search of available medical literature was performed using MedLine- OVID,
CINAHL, and Web of Science. Keywords used included: mechanical ventilation/ respiration, artificial or
acute lung injury, and nebulized heparin or nebulised heparin.
Results: A total of 11 articles were reviewed for relevancy. Two articles were found including one randomized
control study and one prospective observational study. While neither study found improvement in
PaO2:FiO2, one study found significant improvement in ventilator free days. The overall quality of the studies
was very low and further studies with large, randomized control trials will need to be completed.
Conclusion: There isn’t enough data available yet on nebulized heparin to recommend routine use as
adjunctive treatment for ALI. Standard lung function markers like PaO2:FiO2 may not be the most useful
marker for nebulized heparin trials. Larger, longer randomized control trials need to be completed for further
study using patient important outcomes such as ventilator free days.
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Abstract   
 
Background: Acute lung injury (ALI) is a serious clinical concern brought on by inflammatory 
triggers and is characterized by rapid onset of respiratory distress in the setting of inflammatory 
insult. Fibrin deposition from the inflammation leads to poor ventilation and perfusion. There is 
no current treatment for ALI other than supportive measures. Heparin is an anticoagulant that 
prevents fibrin deposition. Previous animal and ALI model studies have demonstrated 
improvement in lung function markers with nebulized heparin. This review looks at the effects of 
nebulized heparin in treating ALI in mechanically ventilated patients. 
 
Methods:  An exhaustive search of available medical literature was performed using MedLine- 
OVID, CINAHL, and Web of Science. Keywords used included: mechanical ventilation/ 
respiration, artificial or acute lung injury, and nebulized heparin or nebulised heparin. 
 
Results:  A total of 11 articles were reviewed for relevancy. Two articles were found including 
one randomized control study and one prospective observational study. While neither study 
found improvement in PaO2:FiO2, one study found significant improvement in ventilator free 
days. The overall quality of the studies was very low and further studies with large, randomized 
control trials will need to be completed. 
 
Conclusion:  There isn’t enough data available yet on nebulized heparin to recommend routine 
use as adjunctive treatment for ALI. Standard lung function markers like PaO2:FiO2 may not be 
the most useful marker for nebulized heparin trials. Larger, longer randomized control trials need 
to be completed for further study using patient important outcomes such as ventilator free days. 
 
Keywords:  Mechanical ventilation, artificial respiration, acute lung injury, nebulized heparin, 
nebulised heparin 
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Nebulized Heparin for Adjunctive Treatment of Mechanically 
Ventilated Patients in the ICU 
 
BACKGROUND 
 Acute lung injury (ALI) is a very serious clinical problem that affects many patients in 
hospitals and intensive care units (ICU) all over the nation. An estimated 190 600 cases of ALI 
develop each year in the United States alone. 1 More than 74 500 deaths are attributed to ALI 
yearly, with the 28-day mortality being 32%.1,2 Acute lung injury is usually brought on by 
inflammatory triggers of lung damage. The list of triggers is extensive and includes pneumonia, 
sepsis, aspiration, trauma, cardiopulmonary bypass, transfusion, hypotension, and more. 2-4 ALI 
is characterized by rapid onset of respiratory distress in the setting of these inflammatory insults. 
1,5 The inflammatory insult leads to fibrin deposition in the alveoli and microvasculature of the 
lungs–leading to thrombosis and possible ischemic tissue in the lungs. 3,6-8 The deposition of 
fibrin and subsequent thrombosis then leads to impaired ventilation and perfusion. 9-11 Fibrin is 
also pro-inflammatory and can lead to increased inflammatory mediators depositing in the lungs. 
12 Mechanical ventilation is used in the ICU for patients unable to breathe for themselves or 
those who have difficulty oxygenating. ALI is present in 18% of patients with prolonged 
mechanical ventilation and ALI will subsequently develop in 26%.13 There is currently no 
standard of care to treat or prevent ALI.14 
 Heparin is a systemic anticoagulant used widely in practice for its results and cost 
effectiveness. It is the drug of choice in a hospital setting due to its ability to be rapidly reversed 
if there was ever a concern for excessive bleeding. Heparin has been shown to reduce fibrin 
deposition in the lungs. 15 Heparin has also been found to reduce pulmonary edema and 
leukocyte activation. 16,17 The efficacy of IV heparin as an adjunctive treatment for ALI has 
already been assessed and was found to provide no significant improvement. 15 Nebulizing 
medication improves delivery to the bronchial tree and could therefore reduce potential for 
systemic bleeding associated with IV heparin use. 12 In animal and ALI lung models, nebulized 
heparin has shown improvement in PaO2:FiO2 and reduced levels of coagulation in the lungs.18 
 There is a large need for an effective treatment or preventative medication for ALI. 
Current supportive care treatment still results in tens of thousands of deaths yearly. This 
systematic review sets out to determine if nebulized heparin will improve the PaO2:FiO2 in 
mechanically ventilated patients in the ICU at high risk of or currently suffering from ALI. 
 
METHODS 
An exhaustive search of the literature was performed using MedLine-OVID, CINAHL, 
and Web of Science. Keywords used included: mechanical ventilation/respiration, artificial or 
acute lung injury, and nebulized heparin or nebulised heparin. Bibliographies of studies and 
other relevant articles were searched for further sources. Studies were required to use nebulized 
heparin in mechanically ventilated patients, be on human subjects, and be in the English 
language. Articles were assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE).19 
 
RESULTS 
A total of 11 articles were found on initial search. After eliminating those that did not fit 
eligibility criteria, seven were reviewed for relevancy. Two articles fit inclusion criteria, 
including one randomized controlled trial12 and one prospective observational study with an 
additional addendum. 14,20 Two studies21,22 were found that utilized nebulized heparin in 
conjunction with nebulized N-acetylcysteine, but both were excluded due to differences in 
therapy type. No additional articles were found by searching the references of the included 
studies.  
 
Dixon et al, 2008 
 In this prospective observational study14 the authors looked at 16 ventilated patients with 
ALI. The purpose of this phase 1 trial was to assess the feasibility, safety, and potential 
anticoagulant effects of nebulized heparin to patients with ALI. The study only included ICU 
patients who were placed on mechanical ventilation for acute respiratory dysfunction 
(characterized by a PaO2:FiO2 of less than 300 mmHg) due to a direct or indirect inflammatory 
insult to the lungs.14 
 Four doses of nebulized heparin were evaluated in this study–50K units/day, 100K 
units/day, 200K units/day, and 400K units/day. There were four patients in each group. The 
patients in the 50K units/day, 100K units/day, and 200K units/day groups received the total 
heparin units in two separate doses spaced 12 hours apart. The patients in the 400K units/day 
group received 100K units every 6 hours. Heparin was nebulized over a course of 30 minutes. 
The study drug was given for two days. Patients were ventilated in pressure support mode with 
upper pressure levels maintained at or below 35 cmH20.14 
 Outcomes that were measured that assessed lung function included PaO2:FiO2, lung 
compliance, and alveolar dead space fraction. In a previous study by Nuckton et al,9 alveolar 
dead space fraction was found to possibly reflect the extent of microvascular thrombosis in ALI–
therefore serve as a potential marker for the anticoagulant effects of nebulized heparin. 9 
Activated partial thromboplastin time (APTT) and thrombin clotting time (TCT) were measured 
to assess for anticoagulant effects. To assess lung hemostatic response, bronchoalveolar lavage 
(BAL) fluid was collected and the authors measured prothrombin fragments (PTF) and tissue 
plasminogen activator (t-PA).14 
 The data analysis demonstrated that there was no statistically significant difference in 
lung function (PaO2:FiO2, lung compliance, and alveolar dead space fraction) between the doses 
or between dosage and time. 14 While APTT and TCT showed a trend of increasing with 
increasing nebulized heparin dose, the findings were not statistically significant (P=0.09 and 
P=0.1). 14 Both values began to normalize following cessation of nebulized heparin. The PTF 
levels in the BAL remained similar to baseline in the 100K units/day, 200K units/day, and 400K 
units/day groups while they were elevated in the 50K units/day group following final 
nebulization compared to baseline (P = 0.1, analysis of variance, comparison by dose). 14 The 
authors suggest that while this is inconclusive, it still leaves the possibility that administering 
nebulized heparin at higher doses limits coagulation activation in the lungs.14 
The authors of this study found that administering nebulized heparin to mechanically 
ventilated patients with ALI was feasible, not associated with serious adverse events, and 
increased APTT levels at higher doses. 14 They state that the study had three main limitations. 
There was an absence of a control group to allow comparison with the nebulized heparin 
dosages. There was a relatively short duration in which the study drug was administered. Lastly, 
there were a small number of patients in the study, which was due to the need for increased 
caution since nebulized heparin had never been studied in patients with ALI prior to this study. 14 
This small sample size lead to an inability to draw conclusions regarding efficacy or potential 
adverse effects.14 
 
Dixon et al, 2010 
 This randomized, double blind, placebo-controlled trial12 investigated the effect of 25K 
U/5mL nebulized heparin in mechanically ventilated patients versus 0.9% sodium chloride. The 
trial enrolled 50 adult critically-ill patients in the intensive care unit in a single hospital (St. 
Vincent’s Hospital in Melbourne, Australia) who were expected to require more than 48 hours of 
mechanical ventilation. The study drug (heparin vs. normal saline) was continued as long as the 
patient remained intubated, for a maximum of 14 days. The primary outcome was the average 
daily ratio of partial pressure of oxygen to the inspired fraction of oxygen (PaO2 : FiO2). 
Secondary outcomes included ventilator-free days, development of ALI following enrollment, 
tracheostomy rate, vasopressor-free days, acute renal failure rates, lengths of stay in the ICU and 
hospital, and mortality. In addition data was collected on pulmonary lavage fluid via non-
bronchoscopic suction to measure inflammatory markers. 
  Eligibility criteria consisted of patients who were expected to need at least 48 hours 
invasive mechanical ventilation owing to primary respiratory failure or other indications. Patients 
underwent block randomization in groups of 2 to 8 and were stratified by the presence of ALI at 
initial enrollment. The randomization service maintained prognostic balance of patients age, sex, 
APACHE II score, percentage in respiratory failure, percentage with ALI, percentage who had 
aspirated, those on vasopressors, average APTT score, primary diagnosis, and admission source. 
12  
Dosing for this study was based off of previous studies14,20 regarding nebulized heparin 
and their anticoagulant effects.12,14,20Patients were given 5 mL of the study medication every 4 
hours and each dose was nebulized for a total of 30 minutes. If patients were less than 165 cm in 
height, the drug was administered every 6 hours. No dose adjustments were made regardless of 
the patient receiving systemic anticoagulants. Treatment groups were balanced to all baseline 
patient characteristics.  There were 25 patients in each medication arm of the study and all 
patients were included in the final analysis. 12  
Patients were ventilated using pressure controlled mode with a target tidal volume set to 
no more than 8 mL/kg of predicted body weight, a standard of practice at the time of the trial. 
Weaning was attempted and performed using spontaneous pressure support mode. If patients 
were not extubated or showed no sign of clinical improvement after 4 days, tracheostomy was 
considered. If necessary, percutaneous technique was used by the ICU physician to perform the 
tracheostomy. 12  
Despite the fact that the PaO2:FiO2 was higher from day 3 on in the heparin group when 
compared to the placebo group, there was no statistically significant difference in the primary 
outcome (194.2 ± 62.8 vs. 187± 38.6 mm Hg, mean difference 7.2, 95% CI -22.8 to 37.1, P = 
0.6). The use of nitrous oxide (NO) however, was associated with more use in the placebo group 
(5/25 vs. 0/25, RR 0.8, 95% CI 0.7 to .97, P = 0.05). 12 Patients were found to have a higher 
number of ventilator-free days among survivors at day 28 if there were in the heparin group 
(22.6 ± 4.0 vs. 18.0 ± 7.1, treatment difference 4.6, 95% CI 0.9 to 8.3, P = 0.02). 12 While not 
statistically significant, there tended to be lower tracheostomies, reduced development of ALI, a 
higher number of vasopressor free days and a higher number of renal failure free days in the 
heparin group. Both the heparin and the placebo groups had similar secondary outcomes of 
ICU/hospital lengths of stay and mortality.12 
  Those in the heparin group had higher levels of increase in their APTT from baseline 
over the study period (4 [1 to 13] vs. 0 [-1 to 4] seconds, P = 0.02). Pulmonary lavage fluid 
levels of TAT, D-dimer, and other inflammatory markers were all similar. 12  
 The authors state that a possible limitation to the study was that the reason for invasive 
mechanical ventilation was broad. Respiratory failure accounted for 62% of the patients’ 
indication for invasive mechanical ventilation but the rest were due to other reasons such as 
coma or cardiac failure. 12 The authors suggest that a methodological limitation could be the use 
of non-bronchoscopic collection of pulmonary fluid through suction, which has been found not 
to provide an accurate assessment of lung inflammatory markers when compared to 
bronchoscopic techniques. 23 Perhaps the largest limitation is that it was commenced at a single 
center, bringing into question whether or not these results can be reproduced. Therefore, the 
authors suggest further trials to confirm the findings of nebulized heparin shortening the duration 
that a patient is mechanically ventilated as this study has shown nebulized heparin to be a safe 
adjunct for treatment in mechanically ventilated patients.12    
 
DISCUSSION 
 Prolonged mechanical ventilation greatly increases ones risk of developing ALI. 13 The 
inflammatory changes that occur with ALI lead to fibrin deposition in the pulmonary 
microcirculation and alveolar sacs–impairing ventilation and perfusion. 9-12 Heparin is an 
anticoagulant that prevents fibrin deposition, leukocyte activation, and reduces pulmonary 
edema. 16,17 Nebulized heparin has been shown to improve PaO2:FiO2 and reduce histological 
damage in animal model studies of ALI. 15,16,18 As nebulized heparin was previously successful at 
reducing the PaO2:FiO2 in animals, these studies attempted to evaluate the same marker of lung 
function in response to nebulized heparin, in humans.  
 This systematic review was able to assess two studies12,14 that looked at the effect of 
nebulized heparin on the PaO2:FiO2 in mechanically ventilated patients with ALI. While there 
was a trend of improvement in the primary outcome of PaO2:FiO2 in one study, 12 neither study 
was able to show a statistically significant improvement in this lung function marker. However, 
the patient important outcome of mechanical ventilator-free days was statistically significantly 
improved in one study.12The same study12demonstrated that NO was needed by 0% of patients 
administered nebulized heparin as opposed to 16% of patients only receiving placebo. This 
shows improvement in oxygenation capabilities of the lungs. These studies were evaluated using 
the GRADE method and results can be seen in Table 1.  
 While both studies demonstrated a general trend of overall improvement and lack of 
adverse effects from nebulized heparin, they both have limitations. In the 2008 study by Dixon et 
al, 14 the authors were investigating dose dependent effects of nebulized heparin. 14 One major 
flaw was lack of a control group. There were four escalating dose groups of nebulized heparin 
but no standard to compare it to. While all levels of nebulized heparin demonstrated similar 
findings in the measured outcomes, it would have been beneficial to compare that to a control 
group that received no heparin. The study14 also consisted of a small cohort size. This was the 
first study to evaluate the effects of nebulized heparin on human patients with ALI. 14 A small 
cohort size was for safety reasons as the authors wanted to demonstrate caution with a new 
treatment on a new population. By limiting the number of patients enrolled in the study, the 
authors reduced the power of the study. Duration of medication administration was also a 
limitation. Again, due to the study being the first human trial to use nebulized heparin in patients 
with ALI, the authors exercised caution and kept the drug administration to only two days. 14 
This limited the possibility to evaluate for any adverse effects, as well as possible beneficial 
anticoagulant effects. As risk for ALI is still high even after extubation,13 this study would have 
benefited from continuing to monitor patients for an extended period time post extubation or post 
medication administration period. This data could be used to help determine nebulized heparin as 
an effective preventative medication. 
 In the 2010 randomized control trial by Dixon et al, 12 the authors found one of the 
limitations to this study was administration of confounding medications. 12 These other 
administered medications included systemic therapeutic doses of heparin as well as prophylactic 
DVT doses were administered to each group in various amounts following enrollment. Other 
medications including some nebulized treatments were also administered. All of these 
medications could have confounded the measurements of the anticoagulation effects of the 
treatments as well as interfere with the measurement of lung function (PaO2:FiO2). Another large 
limitation to this study was actually a flaw in methods. All patients were included in the analysis 
of outcomes, despite length of time receiving treatment. 12 The rapid rate of extubation witnessed 
in the heparin group is a beneficial outcome for patients and demonstrates rapid improvement in 
lung function. However, this may have limited the power of the study in regards to the primary 
outcome as those patients who were most improved didn’t have a PaO2:FiO2 to be measured post 
extubation. 12 The inclusion criteria for patients being mechanically ventilated were also very 
broad. Mechanical ventilation can be initiated due to many indications including pneumonia, 
sepsis, aspiration, trauma, cardiac failure, and coma. 12 Varying pathology for intubation may 
lead to varying pathology of lung inflammation–despite ventilation causing inflammation on its 
own. This may lead to varying responses to treatment if the underlying pathophysiology is 
different. 
 Mechanical ventilation is an invasive measure that provides oxygenation for patients 
unable to do so on their own. This treatment is necessary but doesn’t come without risk. Those 
who are ventilated are at increased risk of infection, are placed on more sedatives, and are unable 
to participate in as much physical therapy. When to place patients on mechanical ventilation or 
when to wean them off of mechanical ventilation are both clinical decisions. Some patients may 
be able to tolerate a lower PaO2:FiO2 ratio than others–in other words, the total clinical picture of 
a patient will determine their ventilation status, not necessarily one single marker. It is important 
to note that the authors of these studies used PaO2:FiO2 as the primary outcome to evaluate lung 
function and the patients’ response to nebulized heparin. While this marker is an appropriate 
choice to measure lung function, it may not be the most beneficial marker for this clinical 
question. 
Further studies need to be completed in order to better evaluate nebulized heparin in 
mechanically ventilated patients. The overall quality of evidence that these studies provide is 
very low and therefore not very reliable. That being said, future studies need be larger, 
randomized control trials that evaluate patient important outcomes as the primary outcome, as 
opposed to standard lung function markers. The amount of ventilator-free days during a study is 
a patient important outcome that shows whether or not patients were responsive to nebulized 
heparin and can be used to infer whether or not the treatment aided in lung function. That is an 
outcome that benefits the patients, lowers risk of complications, and can be used to determine 
efficacy of nebulized heparin compared to standard supportive treatment. 
 
CONCLUSION 
The effects of nebulized heparin in mechanically ventilated patients at risk of ALI are 
unclear. Although animal studies and ALI models have shown improvement with nebulized 
heparin, not much can be concluded from the very low quality of evidence currently available in 
human trials. The studies did not show significant improvement in PaO2:FiO2, but did show a 
significant trend in improvement in patient important outcomes like ventilator-free days. The 
rapid improvement in ventilation leading to extubation in patients on nebulized heparin is a huge 
step in the right direction for finding treatment for ALI. Current supportive therapy is all that’s 
offered for patients with ALI. If we can find a treatment that will shorten the duration of 
mechanical ventilation, then we can decrease the risk of morbidity and mortality in critically ill 
patients. These studies12,14 also showed that nebulized heparin may be a safe and feasible 
treatment or preventative medication, delivering high amounts of heparin to the lungs with 
reduced risk of systemic anticoagulation. 14 In order for nebulized heparin to be considered in 
patients who are mechanically ventilated as an adjunctive treatment to help improve or stave off 
ALI, further studies need to be completed. 
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Table 1. Characteristics of Reviewed Studies 
 
 
 
 
 
 
a. Lacks a control group 
b. Surrogate outcomes instead of patient important ones 
c. Small sample size 
d. Failed to fully address confounders regarding concomitant medications 
 
 
 
Quality Assessment  
 Downgrade Criteria 
Quality 
Study Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
PaO2:FiO2  Very Low 
Dixon et al, 
200814 Observational  Serious
a Seriousb Seriousc Not serious No Very Low 
Dixon et al, 
201012 RCT  Serious
d Not serious Seriousc Not serious No Low 
